Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191


Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, Gilliland DG, Lodish H.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18962-7. Epub 2005 Dec 19.


MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL.

PLoS Med. 2006 Jul;3(7):e270.


The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M.

Blood. 2008 Apr 1;111(7):3751-9. doi: 10.1182/blood-2007-07-102186. Epub 2008 Jan 23.


Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.

Lu X, Huang LJ, Lodish HF.

J Biol Chem. 2008 Feb 29;283(9):5258-66. Epub 2007 Dec 23.


Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG.

Blood. 2006 Jun 1;107(11):4274-81. Epub 2006 Feb 14.


The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW.

Blood. 2005 Nov 15;106(10):3377-9. Epub 2005 Aug 4.


JAK-2 mutations and their relevance to myeloproliferative disease.

Levine RL, Gilliland DG.

Curr Opin Hematol. 2007 Jan;14(1):43-7. Review.


Activated Jak2 with the V617F point mutation promotes G1/S phase transition.

Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K, Griffin JD, Sattler M.

J Biol Chem. 2006 Jun 30;281(26):18177-83. Epub 2006 Apr 21.


Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.

Yan D, Hutchison RE, Mohi G.

Blood. 2012 Aug 30;120(9):1888-98. doi: 10.1182/blood-2011-09-380808. Epub 2012 Jul 26.


Embryonic stem cell differentiation to hematopoietic cells: A model to study the function of various regions of the intracytoplasmic domain of cytokine receptors in vitro.

Filippi MD, Porteu F, Le Pesteur F, Rameau P, Nogueira MM, Debili N, Vainchenker W, de Sauvage FJ, Kupperschmitt AD, Sainteny F.

Exp Hematol. 2000 Dec;28(12):1363-72.


Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.

Tong W, Zhang J, Lodish HF.

Blood. 2005 Jun 15;105(12):4604-12. Epub 2005 Feb 10.


JAK2, the JAK2 V617F mutant and cytokine receptors.

Staerk J, Kallin A, Royer Y, Diaconu CC, Dusa A, Demoulin JB, Vainchenker W, Constantinescu SN.

Pathol Biol (Paris). 2007 Mar;55(2):88-91. Epub 2006 Aug 14. Review.


Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.

Yao H, Ma Y, Hong Z, Zhao L, Monaghan SA, Hu MC, Huang LJ.

Leukemia. 2017 Oct;31(10):2122-2131. doi: 10.1038/leu.2017.1. Epub 2017 Jan 6.


Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.

Levine RL, Wernig G.

Hematology Am Soc Hematol Educ Program. 2006:233-9, 510. Review.


A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.

James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W.

Trends Mol Med. 2005 Dec;11(12):546-54. Epub 2005 Nov 3. Review.


Supplemental Content

Support Center